Loading clinical trials...
Loading clinical trials...
A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome
Conditions
Interventions
SOM230
Locations
17
United States
Ximed Center for Weight Management Ximed Research
La Jolla, California, United States
Stanford University Medical Center SC - SOM230X2203
Stanford, California, United States
Mayo Clinic - Rochester Mayo MN
Rochester, Minnesota, United States
Montefiore Medical Center CLCZ696B2320
The Bronx, New York, United States
Texas Tech University Health Science Center
El Paso, Texas, United States
Virginia Endocrinology Research SC
Chesapeake, Virginia, United States
Start Date
January 8, 2013
Primary Completion Date
August 7, 2015
Completion Date
August 7, 2015
Last Updated
May 10, 2017
NCT01923649
NCT02971631
NCT02525705
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions